newsfilter
← Latest News
Earnings Call Transcripts·

VIATRIS INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VIATRIS INC

biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having Beatrice here. We have the CEO, Scott Smith, the CFO, Paul Campbell, and then the chief R&D officer, Philippe Martin. Welcome. Thank you. Thank You. Maybe to kick things off, how would you characterize this year and the progress that you've made? And you guys just also recently reported Q3. So just remind us of all the great things that are going on so first of all thank you good morning Dennis and thank you for everyone for being here I think 26 has been a been a great year so far for us right we just reported q3 so far this year if we look at the first nine months of 26 versus the first 9 months of 25 we see you know significant revenue growth two to three percent revenue growth we see six percent EBITDA growth we see 8% EPS growth so really transforming the company into a period of sustainable growth. So that's, you know, the financial picture very strong and healthy through the first nine months. We've also transformed the portfolio significantly. We see a margin expansion. We see escalation and acceleration relative to our complex portfolio, complex generics, complex injectables, transdermal patches, particularly estradiol, respiratory devices in the US. So we see us moving from OSD-based generics in the United States to more complex generics with stickier revenue, higher margins, more predictability, longer runways. So very healthy picture in the U.S. We also have made tremendous progress in China this year. Really, really strong growth in China. We've got a great organization there. We have good margins in our Chinese business. It's evolving very, very nicely and growing very, very nicely this year. So we're very pleased with that. Yesterday, we announced the closing of a transaction to acquire Pacero Biosciences, a couple of U.S. in-market accretive assets, high margin, growth prospects going forward. So it fits what we want to do from a business development perspective very, very well. And just when I take a look at the overall picture, a very healthy 26, and I think great momentum as we head into 27 and beyond. Perfect. And earlier this year, you guys had some tremendous growth in China, right? And then in the second half, you guy had messaged that it would slow down a little bit because of some of the various procurement things that are going on there. And you did see a little of that in Q4 or Q3. So maybe just remind us, you know, what you guys are seeing in Q3 and how to think about China in 2027 because that has been a pretty strong driver of your growth. Yeah, so maybe I'll make a general comment and then Paul can talk more specifically about second half of the year. The market in China has sort of been very strong over the last little while. You see sort of for the first time an aging population, a retired population with disposable income, interested in health care, able to acquire and desiring medication, brand name medication, quality medication that they believe, as opposed to Chinese generics. and you see just a very strong overall market. On the innovative side, on the established side, on the generic side, everywhere in China you see a very, very healthy market, and we've made a lot of investments there. I think we've got a very、 very strong team in China that we've invested in. We've invested în e-commerce channels and other things. So we see the combination of a strong market in China evolving, and then we have also made the right investments and have a great team there to take advantage of that evolution in the marketplace. You often see in China when the market is growing that there's policy initiatives which come and those policy initiatives sometimes are executed on a provincial level a little bit differently so the policy environment in China can be a little bit complex overall and we see second half being a little lighter than the first half but overall I think strong growth in 26 and we continue growth in 27 and beyond maybe not at the same rate that we saw in the early part of 26 but we see continuing growth and China being a nice driver for us in the future i don't know paul if you want yeah yeah thanks thanks for the question i'll just add uh you know first half of the year we had 15 16 17 percent growth right year over year um third quarter we said we'd start to moderate there'll be more of an impact with that moderation in q4 over q3 so q3 was 10 year over your growth so we expect kind of mid to high single digit growth in q4 and then what we said is strong momentum as scott said coming out out of 26 into 27 but we expect that growth to go back to you know more historical levels so we're thinking you know low to mid single digit growth year over year but still very strong growth and you can see the impact of that that mixed shift between that and north america which i'm sure we'll talk about in a minute where we're getting you know leverage on the adjusted eva deadline faster than we are on the revenue line. So very excited about that momentum. Another reminder, you know, 50% of our business in China is hospital, about 50%, right? And that's where a lot of the pressure is when these policies come in. And as Scott said, we've done a good job, I think, of shifting, you Know, the market to retail and e-commerce. E-commerce is still growing, you Now, 30%, 40% year over year. It's about 10%, 15% of the business. But we continue to try to grow that. And there's a lot of just brand loyalty for our products, you know, the belief that the quality is there, which we believe, too. But people are willing to pay for it, and we're seeing that positive trend. And I guess an excellent point. I think there's strong brand equity in China in terms of Lipitor, Norvask, Viagra. Some of the world's most iconic brands are doing very, very well for us in China. Perfect. So low to mid-single-digit growth in China overall year over year. But as you go into 2027, the first half you're going to be faced with really, really difficult comps. Do you still think that you can grow year over year, or do you think just the first-half, second-half dynamics net out to? So the way we see things right now, we do believe we'll be able to grow in the first part of the year. It'll be a little bit lower than the second half of the years. But we do expect growth even in Q1 as we stand right now even with that high comp for the year, So, again, strong momentum to the business, and we do expect that to continue. Perfect. And in the U.S., I mean, you mentioned the estradiol patch as being a really nice driver. Maybe characterize for us, you know, what's really driving that growth, how sustainable is it, and, you know, around how big is that revenue stream in the US? Yeah, so when you look at the estrdiol market in the United States, it's about 70% growth versus prior year, driven by, I think, a couple different things. First of all, the removal of black box warnings relative to HRT and hormone replacement therapy in the U.S. And I think there's a belief that this hormone replacement theory can be safely delivered. Patients are engaging in the marketplace at a much greater extent, like I say, 70% growth in the market year over year. And then you also see from a transdermal perspective, you see this movement in the market with the increasing utilization of GLP-1 compounds, which delay gastric emptying. You see a breakdown and a decrease in absorption of things like hormones that are taken orally. So there's really a movement in the marketplace for transdermal delivery. And we are a leader in this market segment. We've seen approximately doubling of our business in that transderma patch area over the past year. So not only is the market growing fast, but we're growing a little bit faster than the market as well so it really is a tremendous opportunity uh you know the issue uh is supply right because it's a sort of unprecedented growth in this marketplace and we've been doing everything we can to increase that supply we were operating uh the plant at the beginning of the year uh 24 5 we've moved to operating at 24 7 uh we have added an additional packaging line or are in the process of adding an additional packing line to help work through some of this bottleneck so So, you know, there's a tremendously strong market out there for these HRT products, particularly transdermals. And we're doing everything we can to meet the market demand that's out there. Yeah. And maybe if I can just add, you knows, it's important to note there's actually three products that we are generic to. When you think about, so when we say estradiol patch, it is sweet, right? It's Minivale, Vivaldot, and Chlamyra that we have. And we also have a vaginal cream that is expanding too. So, when you think about how we disclose our large products, you know, we try to give information on our top ten products. These have not been in that range to date. There are three individual products, so we're going to have to think about, as this growth continues, how we might frame the size of that to our business, because it is growing pretty significantly. And as Scott said, we're doing everything we can to invest, including finding, you know, third-party packagers. I think most immediately we can get additional volume from a third-party packager. The FDA is working with us to get expedited approval to be able to do that and bring that online. And then as we move into mid to the end of 27, we're hoping to put in a second packaging line, as Scott said, at our plant in Vermont to beable to continue that growth. Okay. And I would say, you know, the first two years I was in this job, I never got a single question on yesterday. style of that particular franchise and it's become just because of the growth that you see in that marketplace over the last six, nine months is something that people ask me about all the time. It's important for us to be able to characterize our progress and our performance in this segment because it's becoming very important and we'll look at ways that we can do that without losing competitive advantage. Perfect. And on the supply side, I know it doesn't really impact the U.S. but you guys had some issues and you know at the Nashik facility so maybe talk a little bit about you know what you guys have done to to fix those problems and some of the operational headwinds there so we I'll make a sort of a general comment and then Paul can talk more specifically you know we had a fire in February of this year in that plant there was substantial damage in that plan and so we were in the process of remediating that damage while we were in the progress of remeding that damage the FDA came and did an inspection and had some observations for us so when we looked at all that We thought it was better to take the plant down for a couple months, do the full remediation, and get it back online. Any effect of the Nashik, the plant situation, the shutdown there, is reflected in the guidance that we put out. So we wanted to shut it down, get it remediated, get het remediate fully, and et it back on line as quickly as possible. So it didn't have an impact in 27 as well. Yeah, just to add to what Scott said. so you know in may the the fda came in as we were remediating the fire uh damage and gave us some comments and then in september we got you know a letter from them that the uh the classification the plant was oai so essentially there's could be additional remediation or regulatory activities like a warning letter etc based upon that we made the decision you know as we're remediated too we're finding it was taking longer to remediate so we said hey why don't we just shut the plant down let's do the remediation actions the the additional um you know controls that we put in place let's make sure they're working effectively and then we can you know get the production hopefully january is what we're targeting right now but at least early 27 we don't feel like you know we're going to recoup any uh of that revenue in 27 and we framed it as 100 million dollar impact approximately in 20 uh in third quarter 100 another 100 million in the fourth quarter that's split roughly you know evenly between uh europe and and emerging markets the emerging markets is low mark very low margin arv business but very important uh for people to take that those products in the world so you know we're continuing to to do what we need to do to get ourselves to a point where we can ramp that production up next year as quickly as we can important to note that nashka is one of 25 manufacturing facilities in our network It does relatively low-margin OSD products. There's not a huge U.S. component to it. And that's been a little bit of a headwind to our revenue during the course of the year. But as we've seen the expansion of the estradiol business, China, complex generics in the U.N., those have more than offset any headwinds we've see from the situation in Nashik. What are your base case expectations in terms of getting that plant fully operational and back to pre-fire capacity? I think we're expecting to do that early in 27. Hopefully, either by the end of 26, early 27, that plant will be up and fully operational. Fully operational, but in terms of capacity. Yeah, I was going to say, we expect to start production in January, as we said, and it'll take a little bit of time to ramp that up to full production. Hopefully, end of Q1, maybe end ofQ2, if things progress as we can, we'll get to that point. Then you've got to make the product, then you've Got to get it out on the market, and it will take some time to actually see those sales come back. And how would you approach your 2027 guidance, and what are your assumptions there in terms of the ramp-up in capacity at the National Facility? So if I think about the momentum we have coming out of 26 and going into 27, right, we feel really good about the business overall. A lot of headwinds and tailwinds, but if you just look at us, you know, from an adjusted EBITDA perspective, you look at our midpoint of our revised guidance that we brought up of 4.5, right? and then if you if you look at the momentum in China the momentum in the US that we continue to see with estradiol as an example and octreotide continuing to grow we have the enterprise-wide review going on so additional cost savings we hope to get we have some new products we haven't talked about yet our value-added products we call them so Gwynlo has launched meloxicam we're hoping to get approval by the end of the year we can launched next year you know so a lot of strong momentum uh and then pasira comes on board right persieras is positive to our margins overall you know both both gross margin evita margins uh you know it's a creed of the those so a lotta momentum and as i said as we think about nashik we're not expecting you know recovery of what we've lost we expect basically the same level of revenue in 27 as we got in 26 right now and that's lower margin product so i get a lot of questions well when that comes back online is that going to bring your gross margin back down and i think you know obviously it would have an impact but i don't i don t think it would be uh you know offsetting impact to the to the growth we have in the margin from u.s china and pasir coming on yeah yeah and the plant also supplies a very small proportion of your overall business as well correct it's not like half of your revenue no no no again one of 25 plants yeah exactly uh it doesn't supply a lot particularly to the us uh you know lower margin osd type products and again we hope to have it back online beginning in 27 and sure maybe we can talk a little bit about pacera for a second and then we can obviously segue over to meloxicam um but just you know how like what was the rationale behind that deal why now why today um and how would you leverage that that sales force and you know that us experience going yes so um you know as we were the beginning of 26 as we Were thinking about maloxicam the data came in it was very strong we were very excited about the the data from fast acting maloxi cam um and we were thinking about you know is this something we build ourselves fully do we look for a partner we started you know in the context of that talking to passara about potentially co-promoting the product as we took a look at it i thought it was a good opportunity for acquisition uh into you know exactly the kind of thing that we had communicated that we were looking for in market assets accretive to what we're doing high margin u.s focused business and so you know to me it was the ability or the opportunity to acquire a couple of important assets uh an expo and zolretta uh in again in market high margin accreted products for us but was also an opportunity to acquire capabilities, right? And, you know, we believe that these capabilities will help us from a positive perspective be able to launch Meloxicam. I think there's good positive synergy there. You know, from my perspective, it helps us, you now, increase the ramp sooner in terms of the revenue for Fast-Acting MeloxiCam and maybe a little bit higher peak overall. To me, it's not as much Salesforce synergy as it is some of the access synergy, marketing synergy, medical affairs, you know their ability to in the in the the amount of of people and effort that they have in the hospital environment which is very very strong and so their hospital presence the marketing presence the access presence all those things I think are very important for us to to help us from a positive perspective launch Melox Gamina in a stronger way so again for me when I look at Pacera again exactly what we've been communicating in market assets growing high margin us focused and it was the ability to acquire assets as well as capabilities uh which was important to us as we start to build our us innovative promoter presence and i'll just add you know very important to use that it was you know financially disciplined and balanced right so if you look at the multiple we paid justity but uh on an ltm basis it was like 9.3 percent unsynergized if you synergize that it's like 7.3 which is a little bit below our own uh multiple right now so also leverage ratio we expect very little impact at the end of the year so we're still looking at 2.9 times which is you know even below the midpoint of our 2.8 to 3.2 long term so very financially disciplined which is what we've talked about that we want to do and as Scott said very strategic. Sure, there are for Pacera there's been mostly two major debates among investors. Number one is just how to think about expo growth which you know they report a Q3 and you saw 1.8 percent year-over-year growth that's actually been decelerating so that's been a debate and then the second excuse me and then a second debate is around the durability of the expo business right so how are you thinking about those two dynamics now that you guys are in control of of the products and uh yeah sure i can i can touch on you know from a from a patent landscape perspective right there's obviously a an agreement in place for a volume uh limited uh entry for fursenius in 2030. um since that settlement and this is this is public right this here spent a lot of time working on increasing that patent landscape and getting additional protections so as we worked with them through diligence understand we do feel like they've done a lot good work there so our expectation is that we can bring our expertise that we have in-house you know from many years of fighting patents protecting patents et cetera that we can take it to the next level and hopefully for the the additional filers that are out there that you know we'd be able to kind of push that competition out closer to the mid 2030s would be the hope if when the additional competition would come in and even if it does you know, we would hope that would still be also volume limited in some way so we're hoping to bring that all together to be able, to continue you know some growth on expo you know well into the 2030s okay and then on the near-term growth like um like how do you look at exprel do you look at it as a stable grower or do you hope to accelerate that growth uh you know given your guys's commercial expertise yeah i think there's been some some market dynamics this year that have slowed growth a little bit i think we see it as uh as right now it's in a slow growth phase I think we can accelerate that with our resources, with changes in the marketplace. We see it as being, you know, a strong growth product for us, you know, between now and 2030. Again, a little, some market challenges, you know, this year in particular, but we expect that to dissipate, and we see it as a strong-growth product for US now through 2030. Okay, perfect. Now, if we can talk a little bit about Meloxicam. I believe the PDUFA is sometime in December. what would an ideal label look like to you and how are you thinking about the launch of that product in 27 yeah so paducah is december 27th and hopefully the discussions and interactions with the fda have been going very well relative to specifics of the label i'll ask philippe to comment on that yeah so i think the the key discussion point is around opioid sparing language in the label um we've uh throughout the development of fast acting meloxicam we've had many interaction with the agency where we designed the phase three program specifically to be able to get that data into the label our first two key secondary endpoints were designed around opioid sparing and so we anticipate this data will be included in the clinical study section of the label whether we end up with additional language as part of the Label we'll see we'll have that conversation with the agency but it will not it's not necessary just having that data in the clinical section will allow us to to talk about it right so I think that's that's really the key part the rest a fast onset if you can see on power better than then steroid than and Tramadol, all that should be in the label. And, you know, labels are always interesting, you know, discussion with the agency and negotiation, and you never know exactly how it's going to end up, but to me, the most important thing is the data, and the data is extraordinarily strong. You know, I wouldn't be telling the truth if I didn't say we were quite surprised at how strong the data actually was in terms of the ability, the opioid sparing data, again, that language doesn't necessarily always translate into a label, but when you take a look at the data, very, very strong, and I believe highly differentiated versus anything in the market. I think we've got a great market opportunity with fast-acting meloxicam, sort of a known molecule, new formulation, and very, Very strong data. So we're excited to get out there and get it into the marketplace. Again, as we talked about earlier, I think the Pacera acquisition helps us move that forward faster and better, and I think it shows the confidence that we have in the fast-acting blocks again. Sure. And then how should investors be thinking about price? And then should people benchmark you guys to Vertex's or Navic's launch in the first, let's call it, 12 months? Yeah, I mean, you know, price is something that, you Know, in advance of understanding exactly what the label looks like, I wouldn't really get into that. We were looking at a number of different price points. I think the thing for us, this is a 505B2 filing, right? The approval will be under that. And so, you know, we would expect to have exclusivity in the marketplace for this particular product somewhere in the five, six, seven years. It's not 20 years. And so we will, from a marketing strategy perspective, including pricing, look at getting fast market adoption there. How can we get the best access early? How can we take advantage of the product and really do the maximal commercialization quickly? So, again, I'm not going to get into price. I think you take a look at the data. I think it's highly differentiated versus Journavax. And, again. The specifics around pricing are more to do with what does the label actually look like. And we're looking at fast adoption and doing things that will allow it to be adopted fast. Okay. Perfect. Maybe in the last minute, just remind us of your capital allocation priorities, especially after Pacera, and how are you thinking about BD? So we've been talking about, from a capital allocation strategy perspective, sort of 50-50 equal amounts between giving back to shareholders through dividend and share buybacks and then engaging in business development, right? And if you take a look between now and 2030, the next four or five years, that's $10-12 billion, dollars and we're going to do both right we're we're going to continue to pay the dividend we're going to be opportunistic in terms of our share buyback but we're also going to engage in business development bringing in assets to help us accelerate our growth uh through this period to me the you know the ability to do business development and the opportunities we have are built off the fact that the base business is strong it's producing it's it's moved into a period of of uh you know real growth from a based business perspective. We're throwing off a lot of cash. Again, we're going to be disciplined in terms of our capital allocation, but we are going to continue to look for assets that we can be good owners of, right? Things generally that are in market, accretive, and help us accelerate our growth profile. Perfect. Well, I think that's all the time that we have today, but it's great to see you guys and hope you guys have a good conference. Thank you very much. Thank, thank you.

Company
VIATRIS INC
Keywords
VIATRIS INC